MCM
AXSM icon

MAI Capital Management’s Axsome Therapeutics AXSM Stock Holding History

MAI Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-291
Closed -$49.2K – 2307
2026
Q1 		$49.2K Sell
291
-1
-0.3% -$173 ﹤0.01% 2230
2025
Q4 		$53.3K Buy
292
+1
+0.3% +$140 ﹤0.01% 1977
2025
Q3 		$35.3K Hold
291
– – ﹤0.01% 2124
2025
Q2 		$30.4K Hold
291
– – ﹤0.01% 2140
2025
Q1 		$33.9K Hold
291
– – ﹤0.01% 1944
2024
Q4 		$24.6K Buy
+291
New +$26.8K ﹤0.01% 2125

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MAI Capital Management's AXSM Position: Q2 2026 in Review

MAI Capital Management sold out of Axsome Therapeutics (AXSM) in Q2 2026, closing a stake of 291 shares — an estimated $49.2K sold.

MAI Capital Management first reported a position in AXSM in Q4 2024 and held it in 6 quarters. The position peaked at $53.3K in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • MAI Capital Management reported no remaining Axsome Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 291 Axsome Therapeutics shares in Q2 2026, an estimated $49.2K.
  • MAI Capital Management first reported a position in Axsome Therapeutics in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's Axsome Therapeutics position peaked at $53.3K in Q4 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.